CoChat

Essential Medicines Are More Available than Other Medicines around the Globe

Open access

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The World Health Organization (WHO) promotes the development of national Essential Medicines Lists (EMLs) in order to improve the availability and use of medicines considered essential within health care systems. However, despite over 3 decades of international efforts, studies show an inconsistent pattern in the availability of essential medicines. We evaluated and compared the availability of essential medicines, and medicines not included in national EMLs, at global and regional levels. METHODS: Medicine availability in the public and private sector were calculated based on data obtained from national and provincial facility-based surveys undertaken in 23 countries using the WHO/HAI methodology. The medicines were grouped according to their inclusion ('essential') or exclusion (termed 'non-essential') in each country's EML current at the time of the survey. Availability was calculated for originator brands, generics and any product type (originator brands or generics) and compared between the two groups. Results were aggregated by WHO regions, World Bank country income groups, a wealth inequality measure, and therapeutic groups. FINDINGS: Across all sectors and any product type, the median availability of essential medicines was suboptimal at 61·5% (IQR 20·6%-86·7%) but significantly higher than non-essential medicines at 27·3% (IQR 3·6%-70·0%). The median availability of essential medicines was 40·0% in the public sector and 78·1% in the private sector; compared to 6·6% and 57·1% for non-essential medicines respectively. A reverse trend between national income level categories and the availability of essential medicines was identified in the public sector. INTERPRETATION: EMLs have influenced the provision of medicines and have resulted in higher availability of essential medicines compared to non-essential medicines particularly in the public sector and in low and lower middle income countries. However, the availability of essential medicines, especially in the public sector does not ensure equitable access.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0087576

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Availability (median, interquartile range, maximum-minimum) of any product type (originator brand/generic) of essential and non-essential medicines by World Bank income level*. * LIC: Low income countries, LMIC: Lower-middle income countries, UMIC: Upper-middle income countries.
Figure 1 Availability (median, interquartile range, maximum-minimum) of any product type (originator brand/generic) of essential and non-essential medicines by World Bank income level*. * LIC: Low income countries, LMIC: Lower-middle income countries, UMIC: Upper-middle income countries.CC BY · PubMed Central
Figure 2 Median availability of any product type (originator brand/generic) of essential and non-essential medicines by ATC categories. *Ectoparasiticides, including scabicides, insecticides and repellents, **Anti-inflammatory and anti-rheumatic products, ***Agents acting on the renin-angiotensin system.
Figure 2 Median availability of any product type (originator brand/generic) of essential and non-essential medicines by ATC categories. *Ectoparasiticides, including scabicides, insecticides and repellents, **Anti-inflammatory and anti-rheumatic products, ***Agents acting on the renin-angiotensin system.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 126

Metadata

Authors
Bazargani, Y. T., Ewen, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K.
Affiliations
  • Utrecht University (NL)
  • Health Action International (NL)
Corresponding author
Mantel-Teeuwisse, Aukje K.
Venue
PLoS ONE
Published
2014-02-12
Volume
9
Issue
2
Pages
e87576
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2149749469
Cited by
126
References
31
Citations by year
2026: 8 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 17 · 2021: 13 · 2020: 12 · 2019: 11 · 2018: 7 · 2017: 20 · 2016: 5 · 2015: 6 · 2014: 3
FWCI
28.10
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
essential medicines, drug availability, National List of Essential Medicines, World Health Organization, public sector, private sector, generic drugs, health equity, country income level, WHO regions, therapeutic groups, pharmaceutical access
MeSH terms
Health Services Accessibility, Health Services Needs and Demand, Humans, Global Health, World Health Organization, Private Sector, Public Sector, Drugs, Essential, Prescription Drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Essential Medicines Are More Available than Other Medicines around the Globe. https://app.cochat.ai/papers/10.1371/journal.pone.0087576
The paper
Bazargani, Y. T., Ewen, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Essential Medicines Are More Available than Other Medicines around the Globe. PLoS ONE. https://doi.org/10.1371/journal.pone.0087576

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.